A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

NCT05123482 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

460

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
Biliary Tract Carcinoma
Ovarian Cancer
Endometrial Cancer
Squamous Non-Small Cell Lung Cancer

Interventions

DRUG: AZD8205
DRUG: AZD8205 and AZD2936 (Rilvegostomig)
DRUG: AZD8205 and AZD5305 (saruparib)
DRUG: AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig)
DRUG: AZD8205 in combination with AZD9574
DRUG: AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936)

Sponsor

AstraZeneca